A critical component of the immune system known as T cells that respond to fight infection from the original version of the novel coronavirus appear to also protect against three of the most concerning new virus variants, according to a U.S. laboratory study released on March 30.
A top U.S. scientist said governments should not count on a successful vaccine against COVID-19 being developed anytime soon when deciding whether to ease restrictions imposed to curb the pandemic.
Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.
